Roflumilast
Roflumilast is a drug that acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4. It has anti-inflammatory effects and is used as an orally administered drug for the treatment of inflammatory conditions of the lungs such as chronic obstructive pulmonary disease.
In June 2010, it was approved in the EU for severe COPD associated with chronic bronchitis. In March 2011, it gained FDA approval in the US for reducing COPD exacerbations.Medical uses
Its primary clinical use is in the prevention of exacerbations in severe COPD.Adverse effects
Common adverse effects include:
